C4 Therapeutics, Inc.
C4 Therapeutics, Inc. (CCCC)
Overview
C4 Therapeutics, Inc. is a Watertown, Massachusetts-based clinical-stage biopharmaceutical company trading on Nasdaq under CCCC, focused on targeted protein degradation (TPD) — a drug-development modality that harnesses the body's natural protein-disposal machinery to eliminate disease-causing proteins rather than merely inhibiting them. The company's proprietary TORPEDO platform designs small-molecule "degrader" medicines intended to achieve efficacy and selectivity that conventional inhibitor drugs cannot. As a clinical-stage company, C4 has no approved products and reported net losses of approximately $105.0 million in 2025 and $105.3 million in 2024, funding its pipeline through a combination of capital markets activity and major pharmaceutical partnerships.
What They Do & How They Make Money
C4's lead internal program is cemsidomide, an oral IKZF1/3 degrader being studied in Phase 2 development for multiple myeloma through the MOMENTUM trial, with Phase 1 data showing what the company describes as compelling anti-myeloma activity and a differentiated safety profile versus existing therapies. Its second clinical program, CFT8919, is an oral EGFR L858R degrader for non-small-cell lung cancer, currently in Phase 1 development in Greater China through partner Betta Pharma. Beyond these clinical assets, C4 maintains an earlier-stage discovery pipeline targeting inflammation, neuroinflammation, and neurodegeneration, including brain-penetrant degrader candidates. C4 generates near-term revenue not from product sales but from partnership payments: a collaboration with Roche covering two undisclosed oncology targets, a discovery collaboration with Merck KGaA carrying potential milestones of up to $740 million, a $10 million upfront payment from Betta Pharma for Greater China rights to CFT8919, and a completed research collaboration with Biogen that concluded in June 2023.
Competitive Landscape
C4 competes within the fast-growing but still nascent targeted protein degradation space against other clinical-stage biotechs pursuing similar chemistry, most notably Arvinas and Kymera Therapeutics, both of which have their own degrader platforms and pipelines in overlapping therapeutic areas including oncology. Beyond direct TPD competitors, C4's drug candidates ultimately compete against established standard-of-care therapies (including existing multiple myeloma and EGFR-mutant lung cancer treatments) that patients and physicians currently rely on.
Strategic Strengths & Risks
C4's principal strength is its differentiated, patent-protected TORPEDO platform and the validation it has attracted from major pharmaceutical partners — Roche and Merck KGaA collaborations, in particular, represent meaningful third-party endorsement of the platform's scientific credibility and potential value, worth up to $740 million in the Merck KGaA deal alone. Cemsidomide's early Phase 1/2 data in multiple myeloma also represents genuine clinical proof-of-concept. Set against these strengths are the risks inherent to any clinical-stage biopharmaceutical company: no approved products, continued significant cash burn (roughly $105 million annually), binary clinical trial risk, and a competitive field where Arvinas and Kymera are pursuing parallel approaches in overlapping indications. C4's path to a durable competitive position depends entirely on cemsidomide and CFT8919 successfully advancing through registration trials and gaining regulatory approval.